nodes	percent_of_prediction	percent_of_DWPC	metapath
Varenicline—Cor pulmonale—Riluzole—amyotrophic lateral sclerosis	0.0841	0.131	CcSEcCtD
Varenicline—CHRNA4—peripheral nervous system—amyotrophic lateral sclerosis	0.0165	0.0991	CbGeAlD
Varenicline—Facial paralysis—Riluzole—amyotrophic lateral sclerosis	0.0159	0.0248	CcSEcCtD
Varenicline—CHRNA6—brainstem—amyotrophic lateral sclerosis	0.0154	0.0924	CbGeAlD
Varenicline—CHRNA4—nerve—amyotrophic lateral sclerosis	0.0129	0.0773	CbGeAlD
Varenicline—VIIth nerve paralysis—Riluzole—amyotrophic lateral sclerosis	0.0123	0.0192	CcSEcCtD
Varenicline—Peripheral vascular disorder—Riluzole—amyotrophic lateral sclerosis	0.0103	0.0161	CcSEcCtD
Varenicline—CHRNA4—hindbrain—amyotrophic lateral sclerosis	0.00965	0.0579	CbGeAlD
Varenicline—Urine abnormality—Riluzole—amyotrophic lateral sclerosis	0.00915	0.0142	CcSEcCtD
Varenicline—Hostility—Riluzole—amyotrophic lateral sclerosis	0.00915	0.0142	CcSEcCtD
Varenicline—Osteoporosis—Riluzole—amyotrophic lateral sclerosis	0.00904	0.0141	CcSEcCtD
Varenicline—Suicide attempt—Riluzole—amyotrophic lateral sclerosis	0.00893	0.0139	CcSEcCtD
Varenicline—Gastric ulcer—Riluzole—amyotrophic lateral sclerosis	0.00872	0.0136	CcSEcCtD
Varenicline—Completed suicide—Riluzole—amyotrophic lateral sclerosis	0.00861	0.0134	CcSEcCtD
Varenicline—Urine analysis abnormal—Riluzole—amyotrophic lateral sclerosis	0.00861	0.0134	CcSEcCtD
Varenicline—Platelet count decreased—Riluzole—amyotrophic lateral sclerosis	0.00852	0.0133	CcSEcCtD
Varenicline—Libido increased—Riluzole—amyotrophic lateral sclerosis	0.00833	0.013	CcSEcCtD
Varenicline—CHRNA6—nervous system—amyotrophic lateral sclerosis	0.00807	0.0484	CbGeAlD
Varenicline—Psoriasis—Riluzole—amyotrophic lateral sclerosis	0.00806	0.0125	CcSEcCtD
Varenicline—CHRNA6—central nervous system—amyotrophic lateral sclerosis	0.00777	0.0466	CbGeAlD
Varenicline—Upset stomach—Riluzole—amyotrophic lateral sclerosis	0.00773	0.012	CcSEcCtD
Varenicline—CHRNA6—cerebellum—amyotrophic lateral sclerosis	0.0076	0.0456	CbGeAlD
Varenicline—Cyst—Riluzole—amyotrophic lateral sclerosis	0.00758	0.0118	CcSEcCtD
Varenicline—Paranoia—Riluzole—amyotrophic lateral sclerosis	0.00743	0.0116	CcSEcCtD
Varenicline—Intestinal obstruction—Riluzole—amyotrophic lateral sclerosis	0.00743	0.0116	CcSEcCtD
Varenicline—Haematemesis—Riluzole—amyotrophic lateral sclerosis	0.00729	0.0113	CcSEcCtD
Varenicline—Thrombosis—Riluzole—amyotrophic lateral sclerosis	0.00716	0.0111	CcSEcCtD
Varenicline—Delusion—Riluzole—amyotrophic lateral sclerosis	0.00716	0.0111	CcSEcCtD
Varenicline—Mania—Riluzole—amyotrophic lateral sclerosis	0.00697	0.0108	CcSEcCtD
Varenicline—Extrapyramidal disorder—Riluzole—amyotrophic lateral sclerosis	0.00673	0.0105	CcSEcCtD
Varenicline—CHRNB2—Circadian rythm related genes—SETX—amyotrophic lateral sclerosis	0.00638	0.0335	CbGpPWpGaD
Varenicline—Nephrolithiasis—Riluzole—amyotrophic lateral sclerosis	0.0063	0.00981	CcSEcCtD
Varenicline—Glycosuria—Riluzole—amyotrophic lateral sclerosis	0.00625	0.00973	CcSEcCtD
Varenicline—CHRNB2—medulla oblongata—amyotrophic lateral sclerosis	0.00617	0.037	CbGeAlD
Varenicline—CHRNA6—brain—amyotrophic lateral sclerosis	0.00617	0.037	CbGeAlD
Varenicline—Endocrine disorder—Riluzole—amyotrophic lateral sclerosis	0.00611	0.00951	CcSEcCtD
Varenicline—Accidental injury—Riluzole—amyotrophic lateral sclerosis	0.00572	0.00891	CcSEcCtD
Varenicline—Ventricular extrasystoles—Riluzole—amyotrophic lateral sclerosis	0.00561	0.00873	CcSEcCtD
Varenicline—Thinking abnormal—Riluzole—amyotrophic lateral sclerosis	0.00553	0.00861	CcSEcCtD
Varenicline—CHRNA4—brainstem—amyotrophic lateral sclerosis	0.00553	0.0332	CbGeAlD
Varenicline—CHRNB2—spinal cord—amyotrophic lateral sclerosis	0.0055	0.033	CbGeAlD
Varenicline—Nocturia—Riluzole—amyotrophic lateral sclerosis	0.00546	0.0085	CcSEcCtD
Varenicline—Leukocytosis—Riluzole—amyotrophic lateral sclerosis	0.00539	0.00839	CcSEcCtD
Varenicline—Dysarthria—Riluzole—amyotrophic lateral sclerosis	0.00536	0.00833	CcSEcCtD
Varenicline—Coordination abnormal—Riluzole—amyotrophic lateral sclerosis	0.00516	0.00803	CcSEcCtD
Varenicline—Pulmonary embolism—Riluzole—amyotrophic lateral sclerosis	0.00507	0.00788	CcSEcCtD
Varenicline—Abnormal dreams—Riluzole—amyotrophic lateral sclerosis	0.00501	0.00779	CcSEcCtD
Varenicline—Photophobia—Riluzole—amyotrophic lateral sclerosis	0.00476	0.0074	CcSEcCtD
Varenicline—CHRNB2—nervous system—amyotrophic lateral sclerosis	0.00464	0.0278	CbGeAlD
Varenicline—CHRNA3—nervous system—amyotrophic lateral sclerosis	0.0045	0.027	CbGeAlD
Varenicline—CHRNB2—central nervous system—amyotrophic lateral sclerosis	0.00446	0.0268	CbGeAlD
Varenicline—Hypertonia—Riluzole—amyotrophic lateral sclerosis	0.00444	0.00691	CcSEcCtD
Varenicline—Mental disability—Riluzole—amyotrophic lateral sclerosis	0.0044	0.00684	CcSEcCtD
Varenicline—CHRNB2—cerebellum—amyotrophic lateral sclerosis	0.00436	0.0262	CbGeAlD
Varenicline—Euphoric mood—Riluzole—amyotrophic lateral sclerosis	0.00435	0.00677	CcSEcCtD
Varenicline—CHRNA3—central nervous system—amyotrophic lateral sclerosis	0.00433	0.026	CbGeAlD
Varenicline—Lymphadenopathy—Riluzole—amyotrophic lateral sclerosis	0.00431	0.00671	CcSEcCtD
Varenicline—CHRNA3—cerebellum—amyotrophic lateral sclerosis	0.00423	0.0254	CbGeAlD
Varenicline—Diabetes mellitus—Riluzole—amyotrophic lateral sclerosis	0.00423	0.00658	CcSEcCtD
Varenicline—Deafness—Riluzole—amyotrophic lateral sclerosis	0.00411	0.0064	CcSEcCtD
Varenicline—Eczema—Riluzole—amyotrophic lateral sclerosis	0.00409	0.00637	CcSEcCtD
Varenicline—CHRNA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—KCNJ10—amyotrophic lateral sclerosis	0.00402	0.0211	CbGpPWpGaD
Varenicline—Injury—Riluzole—amyotrophic lateral sclerosis	0.004	0.00622	CcSEcCtD
Varenicline—Libido decreased—Riluzole—amyotrophic lateral sclerosis	0.00397	0.00617	CcSEcCtD
Varenicline—Amnesia—Riluzole—amyotrophic lateral sclerosis	0.00391	0.00609	CcSEcCtD
Varenicline—Increased appetite—Riluzole—amyotrophic lateral sclerosis	0.00391	0.00609	CcSEcCtD
Varenicline—Atrial fibrillation—Riluzole—amyotrophic lateral sclerosis	0.00388	0.00604	CcSEcCtD
Varenicline—Thirst—Riluzole—amyotrophic lateral sclerosis	0.00386	0.00601	CcSEcCtD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—ECE1—amyotrophic lateral sclerosis	0.00382	0.02	CbGpPWpGaD
Varenicline—Arthritis—Riluzole—amyotrophic lateral sclerosis	0.00378	0.00589	CcSEcCtD
Varenicline—CHRNA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GRIA2—amyotrophic lateral sclerosis	0.00371	0.0195	CbGpPWpGaD
Varenicline—Osteoarthritis—Riluzole—amyotrophic lateral sclerosis	0.00368	0.00572	CcSEcCtD
Varenicline—Gastrointestinal haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00368	0.00572	CcSEcCtD
Varenicline—Disturbance in sexual arousal—Riluzole—amyotrophic lateral sclerosis	0.00365	0.00568	CcSEcCtD
Varenicline—CHRFAM7A—nervous system—amyotrophic lateral sclerosis	0.00364	0.0218	CbGeAlD
Varenicline—Migraine—Riluzole—amyotrophic lateral sclerosis	0.00362	0.00563	CcSEcCtD
Varenicline—Affect lability—Riluzole—amyotrophic lateral sclerosis	0.00362	0.00563	CcSEcCtD
Varenicline—Psychotic disorder—Riluzole—amyotrophic lateral sclerosis	0.00359	0.00559	CcSEcCtD
Varenicline—CHRNB2—brain—amyotrophic lateral sclerosis	0.00354	0.0213	CbGeAlD
Varenicline—CHRNB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—KCNJ10—amyotrophic lateral sclerosis	0.00354	0.0186	CbGpPWpGaD
Varenicline—CHRFAM7A—central nervous system—amyotrophic lateral sclerosis	0.0035	0.021	CbGeAlD
Varenicline—Urinary retention—Riluzole—amyotrophic lateral sclerosis	0.0035	0.00544	CcSEcCtD
Varenicline—Mood swings—Riluzole—amyotrophic lateral sclerosis	0.00348	0.00542	CcSEcCtD
Varenicline—CHRNA4—spinal cord—amyotrophic lateral sclerosis	0.00344	0.0206	CbGeAlD
Varenicline—CHRNA3—brain—amyotrophic lateral sclerosis	0.00344	0.0206	CbGeAlD
Varenicline—Liver function test abnormal—Riluzole—amyotrophic lateral sclerosis	0.00339	0.00528	CcSEcCtD
Varenicline—Hypokalaemia—Riluzole—amyotrophic lateral sclerosis	0.00335	0.00521	CcSEcCtD
Varenicline—Breast disorder—Riluzole—amyotrophic lateral sclerosis	0.00332	0.00517	CcSEcCtD
Varenicline—CHRNA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—NEFL—amyotrophic lateral sclerosis	0.00328	0.0172	CbGpPWpGaD
Varenicline—CHRNB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GRIA2—amyotrophic lateral sclerosis	0.00326	0.0171	CbGpPWpGaD
Varenicline—Gastritis—Riluzole—amyotrophic lateral sclerosis	0.00325	0.00506	CcSEcCtD
Varenicline—Abdominal distension—Riluzole—amyotrophic lateral sclerosis	0.0032	0.00498	CcSEcCtD
Varenicline—Dysphagia—Riluzole—amyotrophic lateral sclerosis	0.00318	0.00495	CcSEcCtD
Varenicline—Asthma—Riluzole—amyotrophic lateral sclerosis	0.00318	0.00495	CcSEcCtD
Varenicline—Angina pectoris—Riluzole—amyotrophic lateral sclerosis	0.0031	0.00482	CcSEcCtD
Varenicline—Bronchitis—Riluzole—amyotrophic lateral sclerosis	0.00306	0.00476	CcSEcCtD
Varenicline—Abdominal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00305	0.00474	CcSEcCtD
Varenicline—CHRNA6—Transmission across Chemical Synapses—KCNJ10—amyotrophic lateral sclerosis	0.00302	0.0158	CbGpPWpGaD
Varenicline—CHRNA7—nervous system—amyotrophic lateral sclerosis	0.00294	0.0176	CbGeAlD
Varenicline—Pollakiuria—Riluzole—amyotrophic lateral sclerosis	0.00294	0.00457	CcSEcCtD
Varenicline—Erectile dysfunction—Riluzole—amyotrophic lateral sclerosis	0.00293	0.00455	CcSEcCtD
Varenicline—Photosensitivity reaction—Riluzole—amyotrophic lateral sclerosis	0.0029	0.00451	CcSEcCtD
Varenicline—CHRNA4—nervous system—amyotrophic lateral sclerosis	0.0029	0.0174	CbGeAlD
Varenicline—Weight increased—Riluzole—amyotrophic lateral sclerosis	0.00289	0.0045	CcSEcCtD
Varenicline—CHRNB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—NEFL—amyotrophic lateral sclerosis	0.00288	0.0151	CbGpPWpGaD
Varenicline—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.00283	0.00441	CcSEcCtD
Varenicline—Infestation—Riluzole—amyotrophic lateral sclerosis	0.00283	0.00441	CcSEcCtD
Varenicline—CHRNA7—central nervous system—amyotrophic lateral sclerosis	0.00283	0.017	CbGeAlD
Varenicline—Depression—Riluzole—amyotrophic lateral sclerosis	0.00283	0.0044	CcSEcCtD
Varenicline—Acute coronary syndrome—Riluzole—amyotrophic lateral sclerosis	0.00279	0.00435	CcSEcCtD
Varenicline—CHRNA4—central nervous system—amyotrophic lateral sclerosis	0.00279	0.0167	CbGeAlD
Varenicline—CHRNA6—Transmission across Chemical Synapses—GRIA2—amyotrophic lateral sclerosis	0.00279	0.0146	CbGpPWpGaD
Varenicline—CHRFAM7A—brain—amyotrophic lateral sclerosis	0.00278	0.0167	CbGeAlD
Varenicline—Myocardial infarction—Riluzole—amyotrophic lateral sclerosis	0.00278	0.00432	CcSEcCtD
Varenicline—Stomatitis—Riluzole—amyotrophic lateral sclerosis	0.00276	0.0043	CcSEcCtD
Varenicline—CHRNA4—cerebellum—amyotrophic lateral sclerosis	0.00273	0.0164	CbGeAlD
Varenicline—CHRNA6—Transmission across Chemical Synapses—SLC1A2—amyotrophic lateral sclerosis	0.00269	0.0141	CbGpPWpGaD
Varenicline—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.00268	0.00417	CcSEcCtD
Varenicline—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.00267	0.00416	CcSEcCtD
Varenicline—CHRNB2—Transmission across Chemical Synapses—KCNJ10—amyotrophic lateral sclerosis	0.00266	0.014	CbGpPWpGaD
Varenicline—Sinusitis—Riluzole—amyotrophic lateral sclerosis	0.00266	0.00414	CcSEcCtD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—ECE1—amyotrophic lateral sclerosis	0.00261	0.0137	CbGpPWpGaD
Varenicline—Bradycardia—Riluzole—amyotrophic lateral sclerosis	0.00259	0.00403	CcSEcCtD
Varenicline—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—KCNJ10—amyotrophic lateral sclerosis	0.00255	0.0134	CbGpPWpGaD
Varenicline—Hallucination—Riluzole—amyotrophic lateral sclerosis	0.00253	0.00394	CcSEcCtD
Varenicline—Hypoaesthesia—Riluzole—amyotrophic lateral sclerosis	0.00253	0.00394	CcSEcCtD
Varenicline—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.00251	0.00391	CcSEcCtD
Varenicline—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.00251	0.0039	CcSEcCtD
Varenicline—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.0025	0.00389	CcSEcCtD
Varenicline—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.00249	0.00388	CcSEcCtD
Varenicline—CHRNA6—Transmission across Chemical Synapses—NEFL—amyotrophic lateral sclerosis	0.00246	0.0129	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—SLC1A3—amyotrophic lateral sclerosis	0.00246	0.0129	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—CHAT—amyotrophic lateral sclerosis	0.00246	0.0129	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—AQP4—amyotrophic lateral sclerosis	0.00246	0.0129	CbGpPWpGaD
Varenicline—CHRNB2—Transmission across Chemical Synapses—GRIA2—amyotrophic lateral sclerosis	0.00245	0.0129	CbGpPWpGaD
Varenicline—CHRNA7—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—KCNJ10—amyotrophic lateral sclerosis	0.00242	0.0127	CbGpPWpGaD
Varenicline—Erythema multiforme—Riluzole—amyotrophic lateral sclerosis	0.00241	0.00374	CcSEcCtD
Varenicline—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.00238	0.0037	CcSEcCtD
Varenicline—CHRNB2—Transmission across Chemical Synapses—SLC1A2—amyotrophic lateral sclerosis	0.00237	0.0124	CbGpPWpGaD
Varenicline—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.00236	0.00367	CcSEcCtD
Varenicline—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GRIA2—amyotrophic lateral sclerosis	0.00235	0.0123	CbGpPWpGaD
Varenicline—CHRNA6—Neuronal System—KCNJ10—amyotrophic lateral sclerosis	0.00231	0.0121	CbGpPWpGaD
Varenicline—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.00231	0.00359	CcSEcCtD
Varenicline—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.0023	0.00358	CcSEcCtD
Varenicline—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00229	0.00357	CcSEcCtD
Varenicline—CHRNA6—Transmission across Chemical Synapses—CHAT—amyotrophic lateral sclerosis	0.00229	0.012	CbGpPWpGaD
Varenicline—CHRNA6—Transmission across Chemical Synapses—SLC1A3—amyotrophic lateral sclerosis	0.00229	0.012	CbGpPWpGaD
Varenicline—Chills—Riluzole—amyotrophic lateral sclerosis	0.00228	0.00355	CcSEcCtD
Varenicline—Arrhythmia—Riluzole—amyotrophic lateral sclerosis	0.00227	0.00354	CcSEcCtD
Varenicline—CHRNA7—brain—amyotrophic lateral sclerosis	0.00224	0.0135	CbGeAlD
Varenicline—CHRNA7—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GRIA2—amyotrophic lateral sclerosis	0.00223	0.0117	CbGpPWpGaD
Varenicline—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.00223	0.00347	CcSEcCtD
Varenicline—CHRNA4—brain—amyotrophic lateral sclerosis	0.00221	0.0133	CbGeAlD
Varenicline—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.00221	0.00345	CcSEcCtD
Varenicline—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.00218	0.0034	CcSEcCtD
Varenicline—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.00217	0.00337	CcSEcCtD
Varenicline—CHRNB2—Transmission across Chemical Synapses—NEFL—amyotrophic lateral sclerosis	0.00217	0.0114	CbGpPWpGaD
Varenicline—Back pain—Riluzole—amyotrophic lateral sclerosis	0.00214	0.00333	CcSEcCtD
Varenicline—CHRNA6—Neuronal System—GRIA2—amyotrophic lateral sclerosis	0.00214	0.0112	CbGpPWpGaD
Varenicline—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.00213	0.00331	CcSEcCtD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—ECE1—amyotrophic lateral sclerosis	0.00213	0.0111	CbGpPWpGaD
Varenicline—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—NEFL—amyotrophic lateral sclerosis	0.00208	0.0109	CbGpPWpGaD
Varenicline—Tremor—Riluzole—amyotrophic lateral sclerosis	0.00207	0.00323	CcSEcCtD
Varenicline—CHRNA6—Neuronal System—SLC1A2—amyotrophic lateral sclerosis	0.00206	0.0108	CbGpPWpGaD
Varenicline—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.00205	0.0032	CcSEcCtD
Varenicline—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.00205	0.00318	CcSEcCtD
Varenicline—CHRNA6—Transmission across Chemical Synapses—SLC6A1—amyotrophic lateral sclerosis	0.00204	0.0107	CbGpPWpGaD
Varenicline—CHRNB2—Neuronal System—KCNJ10—amyotrophic lateral sclerosis	0.00204	0.0107	CbGpPWpGaD
Varenicline—Agitation—Riluzole—amyotrophic lateral sclerosis	0.00203	0.00317	CcSEcCtD
Varenicline—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.00202	0.00315	CcSEcCtD
Varenicline—CHRNB2—Transmission across Chemical Synapses—CHAT—amyotrophic lateral sclerosis	0.00202	0.0106	CbGpPWpGaD
Varenicline—CHRNB2—Transmission across Chemical Synapses—SLC1A3—amyotrophic lateral sclerosis	0.00202	0.0106	CbGpPWpGaD
Varenicline—Malaise—Riluzole—amyotrophic lateral sclerosis	0.002	0.00311	CcSEcCtD
Varenicline—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.00199	0.0031	CcSEcCtD
Varenicline—Syncope—Riluzole—amyotrophic lateral sclerosis	0.00199	0.00309	CcSEcCtD
Varenicline—CHRNA7—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—NEFL—amyotrophic lateral sclerosis	0.00197	0.0103	CbGpPWpGaD
Varenicline—CHRNA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—KCNJ10—amyotrophic lateral sclerosis	0.00197	0.0103	CbGpPWpGaD
Varenicline—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.00196	0.00304	CcSEcCtD
Varenicline—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00195	0.00303	CcSEcCtD
Varenicline—Cough—Riluzole—amyotrophic lateral sclerosis	0.00193	0.00301	CcSEcCtD
Varenicline—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.00192	0.00299	CcSEcCtD
Varenicline—CHRNA3—Transmission across Chemical Synapses—KCNJ10—amyotrophic lateral sclerosis	0.00191	0.01	CbGpPWpGaD
Varenicline—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.00191	0.00297	CcSEcCtD
Varenicline—CHRNA6—Neuronal System—NEFL—amyotrophic lateral sclerosis	0.00189	0.0099	CbGpPWpGaD
Varenicline—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.00189	0.00293	CcSEcCtD
Varenicline—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.00189	0.00293	CcSEcCtD
Varenicline—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.00189	0.00293	CcSEcCtD
Varenicline—CHRNB2—Neuronal System—GRIA2—amyotrophic lateral sclerosis	0.00188	0.00986	CbGpPWpGaD
Varenicline—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.00188	0.00292	CcSEcCtD
Varenicline—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.00187	0.00291	CcSEcCtD
Varenicline—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.00186	0.0029	CcSEcCtD
Varenicline—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.00184	0.00287	CcSEcCtD
Varenicline—CHRNA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GRIA2—amyotrophic lateral sclerosis	0.00182	0.00954	CbGpPWpGaD
Varenicline—CHRNA7—Transmission across Chemical Synapses—KCNJ10—amyotrophic lateral sclerosis	0.00182	0.00953	CbGpPWpGaD
Varenicline—CHRNB2—Neuronal System—SLC1A2—amyotrophic lateral sclerosis	0.00182	0.00953	CbGpPWpGaD
Varenicline—Oedema—Riluzole—amyotrophic lateral sclerosis	0.00181	0.00281	CcSEcCtD
Varenicline—CHRNB2—Transmission across Chemical Synapses—SLC6A1—amyotrophic lateral sclerosis	0.0018	0.00942	CbGpPWpGaD
Varenicline—Infection—Riluzole—amyotrophic lateral sclerosis	0.0018	0.00279	CcSEcCtD
Varenicline—Shock—Riluzole—amyotrophic lateral sclerosis	0.00178	0.00277	CcSEcCtD
Varenicline—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.00177	0.00276	CcSEcCtD
Varenicline—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.00177	0.00275	CcSEcCtD
Varenicline—CHRNA3—Transmission across Chemical Synapses—GRIA2—amyotrophic lateral sclerosis	0.00177	0.00927	CbGpPWpGaD
Varenicline—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00176	0.00274	CcSEcCtD
Varenicline—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.00176	0.00273	CcSEcCtD
Varenicline—CHRNA6—Neuronal System—SLC1A3—amyotrophic lateral sclerosis	0.00175	0.0092	CbGpPWpGaD
Varenicline—CHRNA6—Neuronal System—CHAT—amyotrophic lateral sclerosis	0.00175	0.0092	CbGpPWpGaD
Varenicline—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.00175	0.00272	CcSEcCtD
Varenicline—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.00172	0.00268	CcSEcCtD
Varenicline—CHRNA3—Transmission across Chemical Synapses—SLC1A2—amyotrophic lateral sclerosis	0.00171	0.00895	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—CST3—amyotrophic lateral sclerosis	0.00169	0.00889	CbGpPWpGaD
Varenicline—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.00169	0.00263	CcSEcCtD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—CHAT—amyotrophic lateral sclerosis	0.00168	0.00881	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—AQP4—amyotrophic lateral sclerosis	0.00168	0.00881	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—SLC1A3—amyotrophic lateral sclerosis	0.00168	0.00881	CbGpPWpGaD
Varenicline—CHRNA7—Transmission across Chemical Synapses—GRIA2—amyotrophic lateral sclerosis	0.00168	0.0088	CbGpPWpGaD
Varenicline—CHRNB2—Neuronal System—NEFL—amyotrophic lateral sclerosis	0.00166	0.00871	CbGpPWpGaD
Varenicline—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00165	0.00256	CcSEcCtD
Varenicline—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.00163	0.00254	CcSEcCtD
Varenicline—CHRNA7—Transmission across Chemical Synapses—SLC1A2—amyotrophic lateral sclerosis	0.00162	0.0085	CbGpPWpGaD
Varenicline—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.00161	0.00251	CcSEcCtD
Varenicline—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.00161	0.0025	CcSEcCtD
Varenicline—CHRNA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—NEFL—amyotrophic lateral sclerosis	0.00161	0.00843	CbGpPWpGaD
Varenicline—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.00159	0.00248	CcSEcCtD
Varenicline—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.00157	0.00244	CcSEcCtD
Varenicline—CHRNA6—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	0.00156	0.0082	CbGpPWpGaD
Varenicline—CHRNA3—Transmission across Chemical Synapses—NEFL—amyotrophic lateral sclerosis	0.00156	0.00819	CbGpPWpGaD
Varenicline—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00156	0.00243	CcSEcCtD
Varenicline—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.00156	0.00242	CcSEcCtD
Varenicline—Pain—Riluzole—amyotrophic lateral sclerosis	0.00155	0.0024	CcSEcCtD
Varenicline—Constipation—Riluzole—amyotrophic lateral sclerosis	0.00155	0.0024	CcSEcCtD
Varenicline—CHRNB2—Neuronal System—CHAT—amyotrophic lateral sclerosis	0.00154	0.0081	CbGpPWpGaD
Varenicline—CHRNB2—Neuronal System—SLC1A3—amyotrophic lateral sclerosis	0.00154	0.0081	CbGpPWpGaD
Varenicline—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.00149	0.00232	CcSEcCtD
Varenicline—CHRNA4—Transmission across Chemical Synapses—KCNJ10—amyotrophic lateral sclerosis	0.00148	0.00777	CbGpPWpGaD
Varenicline—CHRNA7—Transmission across Chemical Synapses—NEFL—amyotrophic lateral sclerosis	0.00148	0.00777	CbGpPWpGaD
Varenicline—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.00148	0.0023	CcSEcCtD
Varenicline—CHRNA3—Neuronal System—KCNJ10—amyotrophic lateral sclerosis	0.00147	0.0077	CbGpPWpGaD
Varenicline—CHRNA3—Transmission across Chemical Synapses—CHAT—amyotrophic lateral sclerosis	0.00145	0.00761	CbGpPWpGaD
Varenicline—CHRNA3—Transmission across Chemical Synapses—SLC1A3—amyotrophic lateral sclerosis	0.00145	0.00761	CbGpPWpGaD
Varenicline—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.00144	0.00223	CcSEcCtD
Varenicline—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.00143	0.00222	CcSEcCtD
Varenicline—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.00143	0.00222	CcSEcCtD
Varenicline—CHRNA7—Neuronal System—KCNJ10—amyotrophic lateral sclerosis	0.00139	0.0073	CbGpPWpGaD
Varenicline—CHRNA7—Transmission across Chemical Synapses—CHAT—amyotrophic lateral sclerosis	0.00138	0.00722	CbGpPWpGaD
Varenicline—CHRNA7—Transmission across Chemical Synapses—SLC1A3—amyotrophic lateral sclerosis	0.00138	0.00722	CbGpPWpGaD
Varenicline—CHRNB2—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	0.00138	0.00722	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—CHAT—amyotrophic lateral sclerosis	0.00137	0.00718	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—SLC1A3—amyotrophic lateral sclerosis	0.00137	0.00718	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—AQP4—amyotrophic lateral sclerosis	0.00137	0.00718	CbGpPWpGaD
Varenicline—CHRNA4—Transmission across Chemical Synapses—GRIA2—amyotrophic lateral sclerosis	0.00137	0.00717	CbGpPWpGaD
Varenicline—CHRNA3—Neuronal System—GRIA2—amyotrophic lateral sclerosis	0.00135	0.0071	CbGpPWpGaD
Varenicline—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.00133	0.00207	CcSEcCtD
Varenicline—CHRNA4—Transmission across Chemical Synapses—SLC1A2—amyotrophic lateral sclerosis	0.00132	0.00693	CbGpPWpGaD
Varenicline—CHRNA3—Neuronal System—SLC1A2—amyotrophic lateral sclerosis	0.00131	0.00686	CbGpPWpGaD
Varenicline—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.0013	0.00202	CcSEcCtD
Varenicline—CHRNA3—Transmission across Chemical Synapses—SLC6A1—amyotrophic lateral sclerosis	0.00129	0.00679	CbGpPWpGaD
Varenicline—CHRNA7—Neuronal System—GRIA2—amyotrophic lateral sclerosis	0.00128	0.00674	CbGpPWpGaD
Varenicline—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.00128	0.00199	CcSEcCtD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—BDNF—amyotrophic lateral sclerosis	0.00127	0.00667	CbGpPWpGaD
Varenicline—CHRNA7—Neuronal System—SLC1A2—amyotrophic lateral sclerosis	0.00124	0.00651	CbGpPWpGaD
Varenicline—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.00124	0.00192	CcSEcCtD
Varenicline—CHRNA7—Transmission across Chemical Synapses—SLC6A1—amyotrophic lateral sclerosis	0.00123	0.00644	CbGpPWpGaD
Varenicline—CHRNA4—Transmission across Chemical Synapses—NEFL—amyotrophic lateral sclerosis	0.00121	0.00633	CbGpPWpGaD
Varenicline—CHRNA3—Neuronal System—NEFL—amyotrophic lateral sclerosis	0.0012	0.00627	CbGpPWpGaD
Varenicline—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.0012	0.00186	CcSEcCtD
Varenicline—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.00115	0.00179	CcSEcCtD
Varenicline—Rash—Riluzole—amyotrophic lateral sclerosis	0.00114	0.00177	CcSEcCtD
Varenicline—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00114	0.00177	CcSEcCtD
Varenicline—CHRNA4—Neuronal System—KCNJ10—amyotrophic lateral sclerosis	0.00113	0.00595	CbGpPWpGaD
Varenicline—CHRNA7—Neuronal System—NEFL—amyotrophic lateral sclerosis	0.00113	0.00595	CbGpPWpGaD
Varenicline—Headache—Riluzole—amyotrophic lateral sclerosis	0.00113	0.00176	CcSEcCtD
Varenicline—CHRNA4—Transmission across Chemical Synapses—SLC1A3—amyotrophic lateral sclerosis	0.00112	0.00589	CbGpPWpGaD
Varenicline—CHRNA4—Transmission across Chemical Synapses—CHAT—amyotrophic lateral sclerosis	0.00112	0.00589	CbGpPWpGaD
Varenicline—CHRNA3—Neuronal System—SLC1A3—amyotrophic lateral sclerosis	0.00111	0.00583	CbGpPWpGaD
Varenicline—CHRNA3—Neuronal System—CHAT—amyotrophic lateral sclerosis	0.00111	0.00583	CbGpPWpGaD
Varenicline—Nausea—Riluzole—amyotrophic lateral sclerosis	0.00107	0.00167	CcSEcCtD
Varenicline—CHRNA7—Neuronal System—CHAT—amyotrophic lateral sclerosis	0.00106	0.00554	CbGpPWpGaD
Varenicline—CHRNA7—Neuronal System—SLC1A3—amyotrophic lateral sclerosis	0.00106	0.00554	CbGpPWpGaD
Varenicline—CHRNA4—Neuronal System—GRIA2—amyotrophic lateral sclerosis	0.00105	0.00549	CbGpPWpGaD
Varenicline—CHRNA4—Neuronal System—SLC1A2—amyotrophic lateral sclerosis	0.00101	0.00531	CbGpPWpGaD
Varenicline—CHRNA4—Transmission across Chemical Synapses—SLC6A1—amyotrophic lateral sclerosis	0.001	0.00525	CbGpPWpGaD
Varenicline—CHRNA3—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	0.000991	0.0052	CbGpPWpGaD
Varenicline—CHRNA7—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	0.00094	0.00493	CbGpPWpGaD
Varenicline—CHRNA4—Neuronal System—NEFL—amyotrophic lateral sclerosis	0.000925	0.00485	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—BDNF—amyotrophic lateral sclerosis	0.000869	0.00456	CbGpPWpGaD
Varenicline—CHRNA4—Neuronal System—SLC1A3—amyotrophic lateral sclerosis	0.00086	0.00451	CbGpPWpGaD
Varenicline—CHRNA4—Neuronal System—CHAT—amyotrophic lateral sclerosis	0.00086	0.00451	CbGpPWpGaD
Varenicline—CHRNA4—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	0.000767	0.00402	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—BDNF—amyotrophic lateral sclerosis	0.000708	0.00372	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	0.000635	0.00333	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	0.000539	0.00283	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	0.000434	0.00228	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	0.000368	0.00193	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	0.000354	0.00186	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—TP53—amyotrophic lateral sclerosis	0.000333	0.00175	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	0.0003	0.00158	CbGpPWpGaD
